

REVIEW ARTICLE

CRITICAL CARE MEDICINE

Bleeding and Coagulopathies
in Critical Care

Beverley J. Hunt, M.D.

THE DEFINITION OF COAGULOPATHY IS “A CONDITION IN WHICH THE blood’s ability to clot is impaired.” However, for some clinicians, the term also covers thrombotic states, and because of the complexity of the hemostatic pathways, the two conditions can exist simultaneously. Some practitioners would consider that mildly abnormal results on coagulation screening without bleeding can also indicate a coagulopathy. This review is confined to the original definition of coagulopathy as given above. Such states are common in patients in the intensive care unit (ICU) and require a clinicopathological approach to ensure that the correct diagnosis is made and the appropriate treatment administered. The lack of evidence for managing coagulopathies in critical care is striking. This review will highlight selected areas in which there is high-quality evidence and at the same time point out areas for which there is poor evidence. In the latter case, there is little consensus on management.

From King’s College London and Guy’s and St. Thomas’ Trust — both in London. Address reprint requests to Dr. Hunt at the Thrombosis and Haemophilia Centre, St Thomas’ Hospital, Westminster Bridge Rd., London SE1 7EH, United Kingdom, or at beverley.hunt@gstt.nhs.uk.

N Engl J Med 2014;370:847-59.

DOI: 10.1056/NEJMr1208626

Copyright © 2014 Massachusetts Medical Society.

DIFFERENTIAL DIAGNOSIS

A medical history taking and physical examination are vital, since many different conditions can produce similar laboratory abnormalities. For example, end-stage liver failure and disseminated intravascular coagulation produce thrombocytopenia and similar changes in standard tests of coagulation, and yet the management of and prognosis for these conditions are very different. A peripheral-blood smear is a vital investigation tool in most cases to confirm a low platelet count and the presence or absence of other diagnostic features, such as red-cell fragmentation, platelet morphologic abnormalities, or evidence of dysplasia or hematinic deficiency. Table 1 and Figure 1 highlight the relationship between laboratory findings and various coagulopathies.

Once it has been determined that the underlying cause is not a response to therapeutic agents meant to modify the coagulation response (e.g., treatment with vitamin K antagonists, heparinoids, or direct factor Xa or IIa inhibitors), practitioners need to evaluate the pattern of bleeding, which may include widespread petechiae and mucosal bleeding in platelet disorders, generalized oozing from de-epithelialized surfaces, and fast bleeding from damaged major vessels.

MANAGEMENT OF COAGULOPATHIES

The first principle of the management of coagulopathies in critical care is to avoid the correction of laboratory abnormalities with blood products unless there is a clinical bleeding problem, a surgical procedure is required, or both.

MAJOR BLEEDING

The lack of good-quality evidence is most marked in the use of blood components to manage major bleeding. When blood components were introduced into critical care practice decades ago, their benefit was never assessed in randomized clinical trials.

Table 1. Laboratory Findings in Various Platelet and Coagulation Disorders in the ICU.

Condition	Prothrombin Time	Activated Partial-Thromboplastin Time	Fibrinogen Level	D-Dimer Level	Bleeding Time	Platelet Count	Findings on Blood Smear
Vitamin K deficiency or use of vitamin K antagonist	Prolonged	Normal or mildly prolonged	Normal	Unaffected	Unaffected	Unaffected	
Aspirin or thienopyridines	Unaffected	Unaffected	Unaffected	Unaffected	Prolonged	Unaffected	
Liver failure							
Early stage	Prolonged	Unaffected	Unaffected	Unaffected	Unaffected	Unaffected	
End stage	Prolonged	Prolonged	Low	Increased	Prolonged	Decreased	
Uremia	Unaffected	Unaffected	Unaffected	Unaffected	Prolonged	Unaffected	
Disseminated intravascular coagulation	Prolonged	Prolonged	Low	Increased	Prolonged	Decreased	Fragmented red cells
Thrombotic thrombocytopenic purpura	Unaffected	Unaffected	Unaffected	Unaffected	Prolonged	Very low	Fragmented red cells
Hyperfibrinolysis	Prolonged	Prolonged	Low	Very high	Possibly prolonged	Unaffected	

Later, concern about transfusion-transmitted infections (human immunodeficiency virus infection, hepatitis, and a new variant of Creutzfeldt-Jakob disease) and limitations in the blood supply led to a more restrictive use of blood components.

In the absence of randomized, controlled trials, retrospective studies of military casualties¹ and, later, similar studies of civilian casualties² showing improved survival with transfusion of 1 U of fresh-frozen plasma for each unit of red cells have resulted in earlier administration of an increased number of units of fresh-frozen plasma. However, these studies have been criticized, particularly for methodologic flaws that include survival bias (i.e., patients who did not survive were not transfused with fresh-frozen plasma) and heterogeneity between studies.³

Despite the lack of evidence that bleeding after surgery and gastrointestinal or obstetric hemorrhage are associated with hemostatic changes similar to those in acute traumatic coagulopathy, the early use of a transfusion ratio of fresh-frozen plasma to red cells of 1:1 or 1:2 has become widespread. This increased use of plasma is not risk-free, since the incidence of transfusion-related acute lung injury is increased,⁴ as may be the risk of the acute respiratory distress syndrome (ARDS). In one study involving trauma patients requiring a nonmassive transfusion (<10 U of packed red cells within 12 hours after admission), the administration of more than 6 units of fresh-frozen plasma, as compared with no transfusion, was associated with an increase by a factor of 12 in the rate of ARDS and

an increase by a factor of 6 in the multiple organ dysfunction syndrome.⁵


The critical transfusion ratio of fresh-frozen plasma to red cells in the management of major bleeding is not known. This question is being evaluated in the North American Pragmatic, Randomized Optimal Platelets and Plasma Ratios study (ClinicalTrials.gov number, NCT01545232). This multicenter, randomized trial is comparing the effect of various ratios of blood products administered to trauma patients who are predicted to require massive transfusion (>10 U of packed red cells within the next 24 hours) on rates of death at 24 hours and 30 days. In the interim, a North American–European divide in the practice of using blood components to support hemostasis has emerged. Although in North America there has been increased use of fresh-frozen plasma in patients with major hemorrhage, some European practitioners have abandoned the use of fresh-frozen plasma, relying on the exclusive use of factor concentrates on the basis of rotational-elastometry–guided intervention with prothrombin complex concentrate, factor XIII, and fibrinogen.⁶ In contrast, other practitioners believe that the treatment of major hemorrhage should begin with fibrinogen supplementation with tranexamic acid, a synthetic derivative of the amino acid lysine that acts as an antifibrinolytic agent by competitively inhibiting plasminogen, with red cells and intravenous fluid used on an as-needed basis.⁷

Fibrinogen is a critical molecule in coagulation. It is the protein that ultimately forms fibrin,

the ligand for platelet aggregation, and in patients with major bleeding, it is required to a larger extent than any other hemostatic protein.⁸ In such patients, this requirement reflects increased consumption, loss, dilution, and fibrinogenolysis. On the basis of these multiple roles, even in the absence of evidence from randomized, controlled trials, guidelines for the management of traumatic bleeding now indicate that the trigger level for supplementing fibrinogen should be 1.5 to 2.0 g per liter rather than 1.0 g per liter.⁹ It is unknown whether early fibrinogen supplementation and the use of prothrombin complex concentrate, as compared with the use of fresh-frozen plasma, improves clinical

outcomes in patients with major bleeding. Future randomized, controlled trials should assess the overall benefit and safety, including the rate of hospital-acquired venous thromboembolism.^{10,11} Similarly, the use of recombinant factor VIIa, which has been shown to reduce the use of red cells in bleeding but not to reduce mortality, needs further evaluation. Data from placebo-controlled trials have shown that the off-label use of recombinant factor VIIa significantly increased the risk of arterial thrombosis.^{12,13}

Tranexamic acid should be administered to all patients with major bleeding after trauma. This recommendation is supported by a large, randomized, controlled trial, the Clinical Randomization



of an Antifibrinolytic in Significant Hemorrhage (CRASH-2) study, in which 20,000 trauma patients with bleeding or at risk for major bleeding were randomly assigned to receive either tranexamic acid or placebo. Patients who received tranexamic acid within 3 hours after injury had a one-third reduction in deaths from bleeding.¹⁴ After a secondary analysis of their data, the CRASH-2 investigators recommended that tranexamic acid be administered as soon as possible after injury, since the drug ceased to confer benefit and appeared to be associated with increased mortality if it was administered more than 3 hours after injury.¹⁵ Reassuringly for a hemostatic drug, the incidence of thrombosis after trauma was not increased in the study patients. Strong evidence that tranexamic acid reduced the need for blood transfusion in surgery has been available for years, although the effect of tranexamic acid on thromboembolic events and mortality in such patients remains uncertain.¹⁶

HEMOSTATIC SUPPORT FOR INVASIVE PROCEDURES

There is no supportive evidence for the prophylactic use of fresh-frozen plasma to correct abnormal results on coagulation screening (for prothrombin time, activated partial-thromboplastin time, and fibrinogen) before an invasive procedure. Coagulation screening has no predictive value for later bleeding, and the use of fresh-frozen plasma may not correct abnormal results on coagulation tests. There is currently no consensus on what coagulation-screening results should trigger the use of fresh-frozen plasma, which has led to variation in the use of fresh-frozen plasma by critical care physicians.^{17,18} Thrombin generation, although delayed, is normal or enhanced¹⁹ when the prothrombin ratio is 1.5 or less, so I suggest that a prothrombin ratio of 1.5 or less is satisfactory for the insertion of a central venous or an arterial catheter in patients in whom direct compression can assist with hemostasis without the need for prophylactic supplementation with fresh-frozen plasma.

As a general rule, dietary intake of vitamin K, which is necessary for the formation of coagulation factors II, VII, IX, and X, may be inadequate in critical care settings.²⁰ Despite the lack of high-quality evidence and the inability of vitamin K to correct a coagulopathy caused by liver disease, I recommend supplementation

of vitamin K₁ (at a dose of at least 1 mg orally daily or 10 mg intravenously weekly) for critical care patients at risk.

DISSEMINATED INTRAVASCULAR COAGULATION

Disseminated intravascular coagulation is a clinicopathological diagnosis²¹ of a disorder that is defined by the International Society on Thrombosis and Hemostasis (ISTH) as “an acquired syndrome characterized by the intravascular activation of coagulation with loss of localization arising from different causes.” This condition typically originates in the microvasculature and can cause damage of such severity that it leads to organ dysfunction (Fig. 2). It can be identified on the basis of a scoring system developed by the ISTH (Table 2).

Disseminated intravascular coagulation usually presents as hemorrhage, with only 5 to 10% of cases presenting with microthrombi (e.g., digital ischemia) alone. Whether the condition presents with a thrombotic or bleeding episode depends on its cause and host defenses. Sepsis is the most common cause of disseminated intravascular coagulation in critical care; systemic infection with a range of bacteria from *Staphylococcus aureus* to *Escherichia coli* is known to be associated with this condition. The complex pathophysiology is mediated by pathogen-associated molecular patterns, which generate an inflammatory response in the host through signaling at specific receptors. For example, signaling by means of toll-like and complement receptors initiates intracellular signaling, which results in the synthesis of several proteins (including proinflammatory cytokines). These proteins trigger hemostatic changes, leading to the up-regulation of tissue factor²² and impairment of physiologic anticoagulants and fibrinolysis. Tissue factor plays a critical role in this process, as shown in meningococcal septicemia, in which the level of tissue factor on monocytes at presentation may be predictive of survival.²³ Another study of meningococcal sepsis showed that a large amount of tissue factor was found on monocyte-derived circulating microparticles.²⁴ The up-regulation of tissue factor activates coagulation, leading to the widespread deposition of fibrin and to microvascular thromboses and may contribute to multiple organ dysfunction.

Complex abnormalities of the physiologic anticoagulants occur, and pharmacologic doses of activated protein C, antithrombin, and tissue




Figure 2. Pathogenesis of Disseminated Intravascular Coagulation in Sepsis.

Through the generation of proinflammatory cytokines and the activation of monocytes, bacteria cause the up-regulation of tissue factor as well as the release of microparticles expressing tissue factor, thus leading to the activation of coagulation. Proinflammatory cytokines also cause the activation of endothelial cells, a process that impairs anticoagulant mechanisms and down-regulates fibrinolysis by generating increased amounts of plasminogen activator inhibitor.

Table 2. Diagnostic Scoring System for Disseminated Intravascular Coagulation (DIC).*

Risk assessment: Does the patient have an underlying disorder known to be associated with overt DIC?

If yes, proceed with this algorithm

If no, do not use this algorithm

Order global coagulation tests (prothrombin time, platelet count, fibrinogen, fibrin-related marker)

Score the test results as follows:

Platelet count: 50,000 to 100,000 per mm³, 1 point; <50,000 per mm³, 2 points

Elevated fibrin-related marker (e.g., D-dimer, fibrin degradation products): no increase, 0 points; moderate increase, 2 points; strong increase, 3 points

Prolonged prothrombin time: <3 sec, 0 points; ≥3 sec but <6 sec, 1 point; ≥6 sec, 2 points

Fibrinogen level: ≥1 g per liter, 0 points; <1 g per liter, 1 point

Calculate the score as follows:

≥5 points: compatible with overt DIC; repeat scoring daily

<5 points: suggestive of nonovert DIC; repeat scoring within next 1 to 2 days

* Data are adapted from Toh and Hoots²¹ on the basis of the scoring system developed by the International Society on Thrombosis and Hemostasis.

factor pathway inhibitor appeared to be beneficial in a study of endotoxemia in animals. These promising studies led to major randomized, controlled trials of the supplementation of physiologic anticoagulants with pharmacologic doses of

activated protein C,²⁵ antithrombin,²⁶ and tissue factor pathway inhibitor²⁷ in patients with sepsis. However, the studies showed no reductions in the rates of death and increased bleeding episodes.

The consumption of the coagulation proteins

Table 3. Differential Diagnosis of Thrombocytopenia in the ICU.**First, rule out pseudothrombocytopenia by asking the following question:**

Is the blood sample clotted?

Check for EDTA-dependent platelet antibodies by collecting the sample in an anticoagulant (e.g., citrate)

If pseudothrombocytopenia has been ruled out, ask the following:

Is the patient taking drugs that could lower the platelet count?

Check for receipt of:

Heparin, which may be associated with heparin-induced thrombocytopenia

IIb/IIIa inhibitors (e.g., abciximab, eptifibatide, tirofiban)

Adenosine diphosphate (ADP)–receptor antagonists (e.g., clopidogrel)

Acute alcohol toxicity

Does the patient have a hematinic deficiency (particularly, acute folate deficiency)?**Does the patient have any of the following:**

Sepsis (especially consider)

Human immunodeficiency virus (HIV) infection

Disseminated intravascular coagulation

Major blood loss and hemodilution

Mechanical fragmentation

Post-cardiopulmonary bypass

Intraaortic balloon pump

Renal dialysis

Extracorporeal membrane oxygenation

Immune-mediated disorder

Immune thrombocytopenic purpura

Antiphospholipid syndrome

Post-transfusion purpura

Microangiopathic hemolytic anemia

Disseminated intravascular coagulation

Thrombotic thrombocytopenic purpura

Hemolytic–uremic syndrome

Hypersplenism

Other disorder

Myelodysplastic syndrome

Cancer

Hereditary thrombocytopenia

and platelets produces a bleeding tendency, with thrombocytopenia, a prolonged prothrombin time and activated partial-thromboplastin time, hypofibrinogenemia, and elevated levels of fibrin degradation products, such as D-dimers. The physiologic anticoagulants are also consumed in the process of inhibiting the many activated coagulation factors.¹⁹ In fulminant disseminated intravascular coagulation, the consumption and diminished supply of platelets and coagulation proteins usually results in oozing at vascular access sites and wounds but occasionally causes profuse hemorrhage.

The cornerstone for managing this condition remains the management of the underlying cause (e.g., sepsis). Further management may not be necessary in patients with mild abnormalities in coagulation and no evidence of bleeding. Guidelines for management are based mainly on expert opinion, which suggests replacement of coagulation proteins and platelets in patients who are bleeding. Platelet transfusion is indicated to maintain a platelet level of more than 50,000 per cubic millimeter, along with the administration of fresh-frozen plasma to maintain a prothrombin time and activated partial-thromboplastin time of less than 1.5 times the normal control time and a source of fibrinogen to maintain a fibrinogen level of more than 1.5 g per liter.²⁸

The use of antifibrinolytic agents is contraindicated in the management of disseminated intravascular coagulation, since the fibrinolytic system is required in recovery to ensure the dissolution of the widespread fibrin. Some guidelines recommend the administration of therapeutic doses of unfractionated heparin in patients with a thrombotic phenotype (e.g., gangrene),²⁸ but such recommendations remain controversial because of the difficulties in monitoring treatment in a patient who already has a prolonged activated partial-thromboplastin time; in addition, heparin administration may provoke hemorrhage. Currently, there is insufficient clinical evidence to make a firm recommendation on the use of heparin in patients with disseminated intravascular coagulation.

THROMBOCYTOPENIA

PATHOPHYSIOLOGICAL MECHANISMS

Thrombocytopenia may arise because of decreased production or increased destruction (immune or nonimmune) of platelets, as well as from sequestration in the spleen. Among patients who are admitted to an ICU, the condition occurs in about 20% of medical patients and a third of surgical patients. The cause of this condition is often multifactorial. Patients with thrombocytopenia tend to be sicker, with higher illness-severity scores, than those who are admitted with normal platelet counts.²⁹ Table 3 lists the differential diagnoses of thrombocytopenia in the critical care setting. Given the long list, it is important to identify patients in whom thrombocytopenia requires specific and urgent action (e.g., heparin-induced thrombocytopenia and thrombotic thrombocyto-

penic purpura). Drug-induced thrombocytopenia is a diagnostic challenge, because critically ill patients often receive multiple medications that can cause thrombocytopenia.

A platelet threshold of 10,000 per cubic millimeter for platelet transfusion in patients who are in stable condition is both hemostatically efficacious and cost-effective in reducing platelet-transfusion requirements.³⁰ Patients with sustained failure of platelet production, such as those with myelodysplasia or aplastic anemia, may remain free of serious hemorrhage, with counts below 5000 to 10,000 per cubic millimeter. However, a higher platelet transfusion trigger should be set in patients with other hemostatic abnormalities or increased pressure on platelet turnover or platelet function. If the patient is actively bleeding, then a platelet count of 50,000 per cubic millimeter should be maintained. Among patients who have or are at risk for bleeding in the central nervous system or who are undergoing neurosurgery, a platelet count of more than 100,000 per cubic millimeter is often recommended, although data are lacking to support this recommendation.^{29,30}

Standard platelet counts are produced by cell counters that categorize the cells according to size, but large platelets may be the same size as red cells and thus be categorized as such. Therefore, an immunologic method of platelet counting, in which platelet antigens are labeled with markers that can be detected with the use of flow cytometry, may be helpful in providing a true count.³¹ Since platelet transfusions may lead to immune platelet refractoriness owing to the formation of anti-HLA antibodies, the use of HLA-matched platelets, if available, should produce better platelet counts after transfusion.

IMMUNOLOGIC CAUSES

As a general rule, an abrupt reduction in platelet counts with a history of recent surgery suggests an immunologic cause or adverse transfusion reaction (post-transfusion purpura or drug-induced thrombocytopenia). Heparin-induced thrombocytopenic thrombosis is an uncommon, transient, drug-induced, autoimmune prothrombotic disorder caused by the formation of IgG antibodies that cause platelet activation by the formation of antibodies to complexes of platelet factor 4 and heparin.³²

POST-TRANSFUSION PURPURA

Post-transfusion purpura is a rare bleeding disorder caused by a platelet-specific alloantibody (usually, anti-human platelet antigen 1a [HPA-1a]) in the recipient. HPA-1a reacts with donor platelets, destroying them and also the recipient's own platelets. The majority of affected patients are multiparous women who have been sensitized during pregnancy. Treatments for post-transfusion purpura include intravenous immune (gamma) globulin, glucocorticoids, and plasmapheresis. High-dose intravenous immune globulin (2 g per kilogram of body weight administered over either 2 or 5 days) produces an increased platelet count in about 85% of patients. Large numbers of platelet transfusions may be required to control severe bleeding before there is a response to intravenous immune globulin. There is limited evidence that the use of HPA-1a-negative platelets is more effective than the use of platelets from random donors.³³

THROMBOTIC MICROANGIOPATHIES


Profound thrombocytopenia and microangiopathic hemolytic anemia (red-cell fragmentation) characterize the thrombotic microangiopathies, which includes three major disorders: thrombotic thrombocytopenic purpura, the hemolytic-uremic syndrome, and the HELLP syndrome (characterized by pregnancy-related hemolysis, elevated liver-enzyme levels, and low platelet count). The majority of cases of thrombotic thrombocytopenic purpura are due to a deficiency of a disintegrin and metalloproteinase with thrombospondin type 1 motif 13 (ADAMTS13), a disorder that may be hereditary or caused by autoimmune destruction. The absence of ADAMTS13 results in the persistence of high-molecular-weight von Willebrand factor, which can cause spontaneous platelet aggregation when the protein is subjected to high shear stress. The rate of death in untreated cases is nearly 95%, but with early plasmapheresis, the survival rate is 80 to 90%. The use of rituximab, a chimeric monoclonal antibody against the surface B-cell protein CD20, which leads to destruction of those cells, has been shown to reduce the rate of recurrence of the autoimmune form of this disorder from 57% to 10%.³⁴ Thrombotic thrombocytopenic purpura is a medical emergency and in untreated cases is associated with a rate of death of 90%, usually from myocardial infarction due to platelet thrombi in the coronary

arteries. Thus, an active diagnosis of this disorder or failure to rule it out should lead to urgent plasmapheresis.

LIVER DISEASE

Thrombopoietin and most hemostatic proteins are synthesized in the liver. Thus, reduced hepatic synthetic function results in prolongation of the screening tests of coagulation (particularly the prothrombin time) and reduced platelet counts, although levels of factor VIII and von Willebrand factor are increased.³⁵ Acute alcohol intake inhibits platelet aggregation. In chronic liver disease, there is also increased fibrinolytic potential due to the failure of the liver to metabolize tissue plasminogen activator. In cholestatic liver disease, there is reduced absorption of lipid-soluble vitamins, so reduced amounts of the vitamin K-dependent coagulation factors II, VII, IX, and X are produced. Furthermore, in liver disease, the failure of the normal enzymatic removal of sialic acid from fibrinogen results in dysfibrinogenemia³⁶ (Fig. 3A).

However, in parallel with the reduction in coagulation factors, there is a similar reduction in the production of physiologic anticoagulants. Thus, patients with chronic liver disease and a prolonged prothrombin time are no longer considered to have a deficiency of coagulation factors, since their coagulation is rebalanced and thrombin generation is usually normal.³⁵ In such cases, there is no need to treat prolonged coagulation times in the absence of bleeding. If bleeding does occur in liver disease, then consensus guidelines, which are largely based on consensus expert opinion, recommend blood-component management as determined by the results of testing of the platelet count, prothrombin time, activated partial-thromboplastin time, thrombin time, and fibrinogen. In a recent randomized, controlled trial, investigators compared a liberal red-cell transfusion strategy (hemoglobin level, <9 g per deciliter) and a restrictive strategy (hemoglobin level, <7 g per deciliter) in patients with acute upper gastrointestinal bleeding. Patients who were treated with the restrictive strategy had longer survival






Figure 3. Hemostasis in Hepatic Failure and Renal Disease.

Liver failure (Panel A) leads to complex hemostatic changes, since the liver is the producer of coagulation factors, physiologic anticoagulants, and thrombopoietin, as well as the site of the metabolism of sialic acid residues from fibrinogen, activated coagulation factors, and tissue plasminogen activator. These defects result in poor coagulation reserve, dysfibrinogenemia, and increased fibrinolytic potential. In renal failure (Panel B), decreased production of erythropoietin produces anemia, which results in a loss of axial flow so that the bleeding time is prolonged. The accumulation of uremic toxins results in platelet dysfunction. APTT denotes activated partial-thromboplastin time, PT prothrombin time, TAFI thrombin-activatable fibrinolysis inhibitor, and t-PA tissue plasminogen activator.

(6 weeks) and a lower rate of rebleeding than did those who were treated with the liberal strategy.³⁷ In this study, portal circulation pressures increased significantly among patients in the liberal-strategy group. Although there are no similar studies addressing changes in coagulopathy or thrombocytopenia, it seems sensible to adopt a restrictive approach to the use of fresh-frozen plasma and platelets in patients with acute upper gastrointestinal bleeding. The role of tranexamic acid in patients with gastrointestinal bleeding is under investigation in the ongoing randomized, controlled Hemorrhage Alleviation with Tranexamic Acid–Intestinal System (HALT-IT) trial (NCT01658124). In patients with liver disease and laboratory tests indicating abnormal synthesis of coagulation factors, vitamin K should be routinely administered to aid in the synthesis of coagulation factors.

RENAL DISEASE

Uremic bleeding typically presents with ecchymoses, purpura, epistaxis, and bleeding from puncture sites due to impaired platelet function. The platelet dysfunction is a result of complex changes that include dysfunctional von Willebrand factor, decreased production of thromboxane, increased levels of cyclic AMP and cyclic GMP, uremic toxins, anemia, and altered platelet granules, all of which are necessary for adequate formation of a platelet plug (Fig. 3B). The anemia that commonly accompanies renal disease leads to the loss of laminar flow in arterioles so that red cells no longer push platelets and plasma to the endothelium, leading to prolongation of the bleeding time; treatment of the anemia partially corrects this problem. There is also some evidence of impaired fibrinolysis in patients with renal disease.

In the past, the bleeding time was considered to be the most useful clinical test of coagulation in patients with renal disease, but much of the evidence supporting testing and treatment was derived from poor-quality studies performed more than 30 years ago. We now know that dialysis, especially peritoneal dialysis, improves platelet function. Erythropoietin, cryoprecipitate, conjugated estrogens, desmopressin, and tranexamic acid have all independently been shown to reduce bleeding time.^{38,39} In the past decade, citrate has risen in popularity as a replacement anticoagulant in continuous renal-replacement therapy, with a reduction in bleeding, although data on its safety in patients with liver failure are lacking.⁴⁰

FIBRINOLYTIC BLEEDING

Excessive fibrinolysis that threatens clot integrity is known as hyperfibrinolysis.⁴¹ Abnormal fibrinolytic activity may be overlooked as a cause of bleeding, particularly in liver disease, and the condition is difficult to diagnose because of the absence of a specific routine assay. Clinical suspicion should be high in cases in which bleeding continues despite hemostatic replacement therapy, platelet levels are relatively conserved but fibrinogen levels are disproportionately low, and D-dimer levels are disproportionately high for disseminated intravascular coagulation. Thromboelastography, which may help differentiate fibrinolytic activation from coagulation factor deficiency, is a crude tool, since it detects only the most marked changes.⁴² Fibrinolytic bleeding should be considered particularly in patients with liver disease and disseminated cancers. The use of tranexamic acid, either by infusion or orally (depending on the severity of the problem and the state of the patient), is beneficial in controlling bleeding.

VON WILLEBRAND'S DISEASE

If unexplained bleeding occurs, consideration should be given to the late presentation of an inherited bleeding disorder. A personal and family history of easy bruising and bleeding should be sought. Occasionally, a condition such as mild von Willebrand's disease may present with persistent oozing after an injury or surgery.⁴³

Acquired von Willebrand's disease, which can be caused by several potential mechanisms due to autoantibodies, myeloproliferative and lympho-

proliferative disorders,⁴⁴ or the breakdown of high-molecular-weight von Willebrand factor multimers owing to high intravascular or extracorporeal circuit shear stresses, may also occur in patients in the ICU. This disorder can also be caused by shear stresses on blood flow in extracorporeal circuits, such as those caused by extracorporeal membrane oxygenation⁴⁴ and left ventricular assist devices. Intravascular shear stress from aortic-valve stenosis can cause acquired von Willebrand's disease, leading to gastrointestinal bleeding (Heyde's syndrome).⁴⁵

Acquired von Willebrand's disease is treated with the use of either desmopressin, which stimulates the release of residual stores of von Willebrand factor by endothelial cells, or von Willebrand factor concentrates, with the latter considered to be the more effective therapy.⁴⁶ The use of antifibrinolytic agents may be considered to alleviate mucocutaneous bleeding. Acquired von Willebrand's disease due to high shear stresses requires the removal of the cause of the condition whenever possible.

BLEEDING ASSOCIATED WITH ANTITHROMBOTIC THERAPY

Table 4 summarizes the current antithrombotic drugs, their mechanisms of action, and reversibility.^{47,48} It is difficult to treat a bleeding patient who is receiving an oral anticoagulant such as dabigatran and rivaroxaban, since there is no specific antidote. Studies that have evaluated the reversal of the new oral anticoagulants have been limited to reversal of drug effect with the use of recombinant activated factor VII and prothrombin complex concentrate. Current evidence suggests that prothrombin complex concentrate may be the best option and that it reverses the effects of rivaroxaban better than the effects of dabigatran.^{49,50} General measures such as stopping the antithrombotic medication, documenting the time and amount of the last drug dose, and noting the presence of renal and hepatic impairment are suggested. Management may be aided by obtaining a full blood count and hemostatic screening, along with a specific laboratory test to measure the antithrombotic effect of the drug, if available. If the medication has been recently ingested and there is no specific antidote, oral activated charcoal may be given to absorb any residual drug in the stomach.

Table 4. Common Antithrombotic Agents, Mechanisms of Action, and Reversibility.

Agent	Mechanism of Action	Site of Clearance	Half-Life	Procedure for Immediate Reversal
Aspirin	Irreversible cyclooxygenase inhibitor		20 min but effect will persist for 5 days	Platelet transfusion; consider use of desmopressin
Clopidogrel, prasugrel, ticagrelor	P2Y ₁₂ antagonists	Hepatic	6 to 15 hr	Platelet transfusion
Unfractionated heparin	Indirect anti-Xa and anti-IIa effect; increases the action of antithrombin by factor of 10,000	Cellular and (at higher doses) renal	45–90 min	Protamine (at a dose of 1 mg) neutralizes 80–100 U unfractionated heparin
Low-molecular-weight heparin	Same as for unfractionated heparin but mainly anti-Xa effect	Renal	Approximately 4 hr, with variability among products	Protamine reverses 60% of effect; consider the use of recombinant activated factor VII if there is continued life-threatening bleeding and the time frame suggests there is residual effect
Danaparoid	A heparinoid with ratio of anti-Xa to anti-IIa of >20	Renal	24 hr	No specific antidote; plasmapheresis may be considered for critical bleeding
Fondaparinux	Synthetic pentasaccharide with indirect anti-Xa effect	Renal	17–20 hr	No specific antidote; use of recombinant activated factor VII should be considered for critical bleeding
Bivalirudin	Direct antithrombin effect	Proteolysis by thrombin (80%) with 20% renal excretion	25 min; 1 hr in renal failure	No specific antidote; hemodialysis, hemofiltration, or plasmapheresis may be considered for critical bleeding
Argatroban	Direct thrombin inhibitor	Hepatic	45 min	No specific antidote
Vitamin K antagonists (e.g., warfarin, phenprocoumon, acenocoumarol, phenindione)	Reduction in functional levels of vitamin K–dependent clotting factors (II, VII, IX, and X)	Hepatic	Varies according to drug, with phenprocoumon the longest and acenocoumarol the shortest	Intravenous vitamin K (1 to 5 mg) and prothrombin complex concentrate (25 to 50 U/kg); use of fresh frozen plasma only if prothrombin complex concentrate is not available
Dabigatran	A direct thrombin inhibitor	80% renal	13 hr (range, 11–22 hr); with creatinine clearance <30 ml/min, 22–35 hr	No specific antidote; use of oral activated charcoal if administered within 2 hr after receipt of drug; consider hemofiltration, hemodialysis; if life-threatening bleeding, consider prothrombin complex concentrate, activated prothrombin complex concentrate, and recombinant activated factor VII
Rivaroxaban, apixaban, edoxaban	Direct anti-Xa inhibition	Hepatic and renal	Rivaroxaban, 7–9 hr; apixaban, 9–14 hr	No specific antidote; if life-threatening bleeding, same as for dabigatran

CONCLUSIONS

The management of bleeding in critically ill patients remains a major clinical challenge. The cause of a bleeding problem may be complex and only partially understood, with limited diagnostic tools and management strategies currently available. The absence of robust evidence from clinical trials to guide the management of ac-

quired bleeding disorders is very striking and points to the need for studies to address the many evidence gaps that currently exist.

Dr. Hunt reports receiving consulting fees from Haemonetics and serving as medical director of Lifeblood: the Thrombosis Charity, which receives funds from pharmaceutical companies to help educate health care professionals and the public. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the author are available with the full text of this article at NEJM.org.

REFERENCES

1. Borgman MA, Spinella PC, Perkins JG, et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. *J Trauma* 2007;63: 805-13.
2. Holcomb JB, del Junco DJ, Fox EE, et al. The Prospective, Observational, Multicenter, Major Trauma Transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks. *JAMA Surg* 2013;148:127-36.
3. Rajasekhar A, Gowing R, Zarychanski R, et al. Survival of trauma patients after massive red blood cell transfusion using a high or low red blood cell to plasma transfusion ratio. *Crit Care Med* 2011;39: 1507-13.
4. MacLennan S, Williamson LM. Risks of fresh frozen plasma and platelets. *J Trauma* 2006;60:Suppl:S46-S50.
5. Inaba K, Branco BC, Rhee P, et al. Impact of plasma transfusion in trauma patients who do not require massive transfusion. *J Am Coll Surg* 2010;210:957-65.
6. Innerhofer P, Westermann I, Tauber H, et al. The exclusive use of coagulation factor concentrates enables reversal of coagulopathy and decreases transfusion rates in patients with major blunt trauma. *Injury* 2013;44:209-16.
7. Ziegler B, Schimke C, Marchet P, Stöckermüller B, Schöchl H, Solomon C. Severe pediatric blunt trauma — successful ROTEM-guided hemostatic therapy with fibrinogen concentrate and no administration of fresh frozen plasma or platelets. *Clin Appl Thromb Hemost* 2013; 19:453-9.
8. Hiippala S. Replacement of massive blood loss. *Vox Sang* 1998;74:Suppl 2:399-407.
9. Spahn DR, Cerny V, Coats TJ, et al. Management of bleeding following major trauma: a European guideline. *Crit Care* 2007;11:R17. [Erratum, *Crit Care* 2007;11: 414.]
10. Rourke C, Curry N, Khan S, et al. Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. *J Thromb Haemost* 2012;10:1342-51.
11. Stanworth SJ, Hunt BJ. The desperate need for good-quality clinical trials to evaluate the optimal source and dose of fibrinogen in managing bleeding. *Crit Care* 2011;15:1006.
12. Simpson E, Lin Y, Stanworth S, Birchall J, Doree C, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. *Cochrane Database Syst Rev* 2012;3:CD005011.
13. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. *N Engl J Med* 2010;363:1791-800. [Erratum, *N Engl J Med* 2011;365:1944.]
14. Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. *Lancet* 2010;376: 23-32.
15. CRASH-2 Collaborators. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. *Lancet* 2011;377: 1096-101.
16. Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. *BMJ* 2012;344: e3054.
17. Desborough M, Stanworth S. Plasma transfusion for bedside, radiologically guided, and operating room invasive procedures. *Transfusion* 2012;52:Suppl 1:20S-29S.
18. Hall DP, Lone NI, Watson DM, Stanworth SJ, Walsh TS. Factors associated with prophylactic plasma transfusion before vascular catheterization in non-bleeding critically ill adults with prolonged prothrombin time: a case-control study. *Br J Anaesth* 2012;109:919-27.
19. Collins PW, Macchiavello LI, Lewis SJ, et al. Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. *Br J Haematol* 2006;135:220-7.
20. Holmes MV, Hunt BJ, Shearer MJ. The role of dietary vitamin K in the management of oral vitamin K antagonists. *Blood Rev* 2012;26:1-14.
21. Toh CH, Hoots WK. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview. *J Thromb Haemost* 2007;5: 604-6.
22. Øvstebo R, Aass HC, Haug KB, et al. LPS from *Neisseria meningitidis* is crucial for inducing monocyte- and microparticle-associated tissue factor activity but not for tissue factor expression. *Innate Immun* 2012;18:580-91.
23. Østerud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. *Thromb Haemost* 1983;49:5-7.
24. Nieuwland R, Berckmans RJ, McGregor S, et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. *Blood* 2000;95:930-5.
25. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. *N Engl J Med* 2012;366: 2055-64.
26. Afshari A, Wetterslev J, Brok J, Møller AM. Antithrombin III for critically ill patients. *Cochrane Database Syst Rev* 2008; 3:CD005370.
27. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. *JAMA* 2003;290:238-47.
28. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. *Br J Haematol* 2009;145:24-33.
29. Vanderschueren S, De Weert A, Malbrain M, et al. Thrombocytopenia and prognosis in intensive care. *Crit Care Med* 2000;28:1871-6.
30. Slichter SJ. Evidence-based platelet transfusion guidelines. *Hematology Am Soc Hematol Educ Program* 2007:172-8.
31. Segal HC, Harrison P. Methods for counting platelets in severe thrombocytopenia. *Curr Hematol Rep* 2006;5:70-5.
32. Kelton JG, Arnold DM, Bates SM. Nonheparin anticoagulants for heparin-induced thrombocytopenia. *N Engl J Med* 2013;368:737-44.
33. Allen DL, Samol J, Benjamin S, Verjee S, Tusold A, Murphy MF. Survey of the use and clinical effectiveness of HPA-1a/5b-

- negative platelet concentrates in proven or suspected platelet alloimmunization. *Transfus Med* 2004;14:409-17.
34. Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. *Br J Haematol* 2012;158:323-35.
 35. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. *N Engl J Med* 2011;365:147-56.
 36. Roberts LN, Patel RK, Arya R. Haemostasis and thrombosis in liver disease. *Br J Haematol* 2010;148:507-21.
 37. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. *N Engl J Med* 2013; 368:11-21. [Erratum, *N Engl J Med* 2013; 368:2341.]
 38. Hedges SJ, Dehoney SB, Hooper JS, Amanzadeh J, Busti AJ. Evidence-based treatment recommendations for uremic bleeding. *Nat Clin Pract Nephrol* 2007;3: 138-53.
 39. Mezzano D, Panes O, Muñoz B, et al. Tranexamic acid inhibits fibrinolysis, shortens the bleeding time and improves platelet function in patients with chronic renal failure. *Thromb Haemost* 1999;82:1250-4.
 40. Zhang Z, Hongying N. Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy. *Intensive Care Med* 2012;38:20-8.
 41. Hunt BJ, Segal H. Hyperfibrinolysis. *J Clin Pathol* 1996;49:958. [Erratum, *J Clin Pathol* 1997;50:357.]
 42. Raza I, Davenport R, Rourke C, et al. The incidence and magnitude of fibrinolytic activation in trauma patients. *J Thromb Haemost* 2013;11:307-14.
 43. Cuker A, Connors JM, Katz JT, Levy BD, Loscalzo J. A bloody mystery. *N Engl J Med* 2009;361:1887-94.
 44. Heilmann C, Geisen U, Beyersdorf F, et al. Acquired von Willebrand syndrome in patients with extracorporeal life support (ECLS). *Intensive Care Med* 2012;38:62-8.
 45. Franchini M, Mannucci PM. Von Willebrand disease-associated angiodysplasia: a few answers, still many questions. *Br J Haematol* 2013;161:177-82.
 46. Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. *Blood* 2011; 117:6777-85.
 47. Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. *Am J Hematol* 2012;87:Suppl 1:S141-S145. [Erratum, *Am J Hematol* 2012;87:748.]
 48. Makris M, Van Veen JJ, Tait CR, Mumford AD, Laffan M. Guideline on the management of bleeding in patients on anti-thrombotic agents. *Br J Haematol* 2013; 160:35-46.
 49. Lazo-Langner A, Lang ES, Douketis J. Clinical management of new oral anti-coagulants: a structured review with emphasis on the reversal of bleeding complications. *Crit Care* 2013;17:230.
 50. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. *N Engl J Med* 2012;366:864-6.

Copyright © 2014 Massachusetts Medical Society.

AN NEJM APP FOR iPHONE

The NEJM Image Challenge app brings a popular online feature to the smartphone. Optimized for viewing on the iPhone and iPod Touch, the Image Challenge app lets you test your diagnostic skills anytime, anywhere. The Image Challenge app randomly selects from 300 challenging clinical photos published in NEJM, with a new image added each week. View an image, choose your answer, get immediate feedback, and see how others answered. The Image Challenge app is available at the iTunes App Store.